Technology
MIP is focused on developing therapies to treat inflammatory diseases and syndromes, and to address other therapeutic domains as infectious diseases, neurosciences, metabolic diseases, cardiology and regenerative medicines
MIP is now entering into clinical evaluation of its lead drug candidate SuperMApo/Resolvix for the treatment of the rare orphan disease systemic scleroderma, concomitantly to Crohn’s disease and multiple sclerosis
Other indications with SuperMApo lead drug candidate are under pre-clinical evaluation
New bio-identical candidates derived from Human cells as well as ATMP are under development

A bio-identical drug
Due to its Human source, SuperMApo lead drug candidate is composed of factors identical to those presented in the human body, making it well tolerated and safe. SuperMApo lead drug candidate is composed of all factors necessary to cure inflammation

Restoring resolution of inflammation
Inflammation resolution is dysregulated in many inflammatory disorders and pathological situations. MIP’s SuperMApo lead drug candidate deeply reeducates the immune system to restore resolution, inflammation arrest and tissue healing

One treatment, one cure
Based on preclinical data, SuperMApo lead drug candidate unique treatment is efficient to cure inflammatory disorders, long-term. Such curative properties of MIP’s lead drug candidate will be confirmed in clinic early 2022, clinical batch production is ongoing
Pipeline
Common and rare inflammatory disorders
Development | Pre-clinical | Phase I/II |
- Systemic sclerosis
- Crohn’s disease
- Multiple sclerosis
Infectious
Development | Pre-clinical | Phase I/II |
- COVID19
Patient’s benefits
Unique
MIP’s technology is a breakthrough approach to produce bio-identical drug candidates for the treatment of non curable diseases such as inflammatory diseases
Efficient
Preclinical data demonstrate the curative properties of MIP’s lead candidate SuperMApo in the context of experimental scleroderma, colitis, arthritis and multiple sclerosis
Expertise
MIP expertise is built on active science researches related to resolution and inflammation, cells and factors essentials to terminate inflammation, and restore functional tissues
Bio-identical
By their Human origin and composition, SuperMApo bio-identical drug represents well tolerated, safe and Human-derived medicine with elevated therapeutic potentials